| pubmed-article:10435727 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0002875 | lld:lifeskim |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:10435727 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:10435727 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10435727 | pubmed:dateCreated | 1999-10-8 | lld:pubmed |
| pubmed-article:10435727 | pubmed:abstractText | The pharmacokinetics of busulphan were studied in 23 thalassaemic children undergoing BMT. Patients received busulphan at a dose of either 16 mg/kg with cyclophosphamide and ATG (Group A) or 600 mg/m2 (with cyclophosphamide alone) (Group B) in 16 divided doses every 6 h over 4 days. Busulphan levels were analyzed by a modified GC-MS method. The dose of busulphan/kg for patients in group B was 64% (range 56-71%) higher than that for patients in group A. The mean AUC, Css, Cmax and MRV were significantly higher in group B as compared with group A for both doses 1 and 13. There was no significant difference in Vd/F, T1/2 and Kel between the two groups. A significant decrease in AUC and Css was found between 1st and 13th doses in group B, but not in group A. The Cl/F values in group A were significantly higher than those in group B after dose 1, but not after dose 13. No increase in toxicity due to the higher dose of busulphan was noted. We conclude that busulphan at 600 mg/m2 results in much higher systemic exposure to the drug as compared to 16 mg/kg, without increase in toxicity in children with beta thalassaemia major. | lld:pubmed |
| pubmed-article:10435727 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10435727 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10435727 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10435727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10435727 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10435727 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10435727 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:Krishnamoorth... | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:SrivastavaAA | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:DennisonDD | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:Kanagasabapat... | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:ChandyMM | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:AigrainE JEJ | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:PoonkuzhaliBB | lld:pubmed |
| pubmed-article:10435727 | pubmed:author | pubmed-author:QuerninM HMH | lld:pubmed |
| pubmed-article:10435727 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10435727 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:10435727 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10435727 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10435727 | pubmed:pagination | 5-11 | lld:pubmed |
| pubmed-article:10435727 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:meshHeading | pubmed-meshheading:10435727... | lld:pubmed |
| pubmed-article:10435727 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10435727 | pubmed:articleTitle | Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. | lld:pubmed |
| pubmed-article:10435727 | pubmed:affiliation | Department of Hematology, Christian Medical College and Hospital, Vellore, Nadu, India. | lld:pubmed |
| pubmed-article:10435727 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10435727 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10435727 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10435727 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10435727 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10435727 | lld:pubmed |
